Our CEO Anthony Finbow has been appointed Vice Chairman of the newly formed BIA (UK BioIndustry Association) Genomics Advisory Committee. The committee has been established to support the strategic objective that the UK starts, scales and builds world leading genomic businesses.

The Committee will act as a leadership platform for sharing and discussing issues of common concern between genomic businesses and will provide expert advice on important issues such as the use of data and embedding genomic medicine in the NHS.

Other companies and organisations represented on the committee include Congenica, Genomics plc, Global Gene Corp, LGC ltd, NewGene ltd, Oxford Nanopore Technologies ltd and the Wellcome Sanger Institute.

Anthony commented, “I am delighted to participate in the BIA Genomics Advisory Committee and look forward to contributing our expertise to help identify and meet the collective challenges faced by the genomics industry.”

The meeting of the Genomics Advisory Committee will take place alongside those of seven other BIA Advisory Committees focussed on the respective issues of Cell and Gene Therapy, Engineering Biology, Finance and Tax, Intellectual Property, Manufacturing, Regulatory Affairs and Science and Innovation.